Publications
Search
Vascular Disease Management, CardioVascular
09/26/2025
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Dr Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Annals of Long-Term Care
09/26/2025
A neurology-forward multidisciplinary care model in long-term care significantly reduced hospitalizations and emergency visits among residents with dementia, demonstrating a replicable approach to improving neuropsychiatric outcomes and quality of life.
Veterans Health Today
09/26/2025
The Department of Veterans Affairs (VA) has awarded more than $818 million in grants to 235 organizations nationwide, a sweeping investment aimed at preventing and reducing homelessness among veterans and their families.
First Report Managed Care
09/26/2025
Rural health care staff members don’t just wear many hats—they often wear them all at once. In many communities, one person might be handling registration, billing, and collections while also answering phones or covering a front desk. When resources are stretched that thin, time becomes one of the most valuable—and scarce—commodities a hospital has.
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.
Pharmacy Learning Network
09/26/2025
Respiratory syncytial virus (RSV) vaccination among US adults aged 60 and older during the 2023 to 2024 season prevented an estimated 1930 deaths, 23 630 hospitalizations, and 18 326 emergency department visits—benefits that could triple with uptake rates matching those of influenza vaccination.
First Report Managed Care
09/26/2025
To succeed under new CMS value-based care models, hospitals must close the “post-acute black hole” by improving data exchange, strengthening care transitions, building high-quality post-acute partnerships, and leveraging predictive and collaborative tools to ensure accountability and better patient outcomes.
Cath Lab Digest, CardioVascular
09/26/2025
Join Bailey Ann Richardson, NP-C, RNFA, CNOR, RCIS, and Drs Morton Kern and Arnold Seto, in a SCAI 2025 discussion that highlights four trials across the interventional cardiology spectrum.
EMSWorld
09/26/2025
Human trafficking has been around forever, but thankfully emergency responders are more equipped than ever to recognize the signs and intervene.
Vascular Disease Management, CardioVascular
09/26/2025
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
Journal of Invasive Cardiology, CardioVascular
09/26/2025
Video Supplement to "Leadless Pacemaker Placement Through the Subclavian Vein: An Alternative to the Femoral Route" (Clinical Image).
First Report Managed Care
09/26/2025
As the asthma treatment landscape evolves, payers must navigate the balance between broad access to foundational therapies and tight controls on high-cost biologics. Our latest Formulary Frontlines analysis compares how Blue Cross Blue Shield, Cigna, and UnitedHealthcare manage coverage across key anti-inflammatory drug classes—revealing striking differences in tiering, utilization tools, and access strategies.
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem cell transplantation.
Journal of Invasive Cardiology, CardioVascular
09/26/2025
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
EMSWorld, Emergency & Mobile Medicine
09/26/2025
480,000 people in the United States suffer injuries from burns, with 45,000 hospitalized and upwards of 3,200 dying, each year; prehospital plasma may help outcomes.
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Journal of Clinical Pathways
09/26/2025
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
Oncology, Lymphoma, Leukemia & Myeloma Network
09/26/2025
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Upcoming Events
October 3 – October 5
October 9 – October 10
October 10 – October 12
October 11 – October 12
October 11 – October 12
October 13 – October 15
October 14 – October 17
October 17 – October 19
October 18
October 20 – October 24
